Amgen
Amgen discovers, develops, manufactures and delivers human therapeutics for patients suffering from serious illnesses.
Business Model:
Revenue: $26.3B
Employees: 10,001-999,999
Industries / Tags:
Detailed Amgen Information
Geographic Data
Address: One Amgen Center Drive
City: Thousand Oaks
State: CA
Zip: 91320
Country: US
Financial Info
Stage:
post ipo debt
Raised Last:
$29B
Raised Total:$4B
Social
Metrics
178,407Website Global Rank
289,646Website Monthly Traffic
Twitter Followers
Description
Amgen discovers, develops, manufactures and delivers human therapeutics for patients suffering from serious illnesses.
Contact Phone:
+18054471000
Contact Email:
Amgen went public on 6/24/1983 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
6/24/1983
Ticker Symbol:
AMGN
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2016 | eHealth Ventures | Corporate Round | - |
| 1/2017 | SiteOne Therapeutics | Series B | 0 |
| 12/2019 | Keck Graduate Institute | Grant | 1M |
| 12/2020 | SomaLogic | Series A | 0 |
| 6/2017 | Darmiyan | Non Equity Assistance | 800k |
| 8/2020 | Science 37 | Venture Round | 0 |
| 10/2019 | BeiGene | Post-IPO Equity | 2.7B |
| 3/2016 | Unilife Corporation | Post-IPO Debt | 30M |
| 10/2018 | Oxford Nanopore Technologies | Venture Round | 65.1M |
| 1/2017 | immatics biotechnologies | Series E | 30M |
| 10/2017 | immatics biotechnologies | Series E | 58M |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 10/2022 | Neumora Therapeutics | Series B | 0 |
| 10/2021 | Neumora Therapeutics | Corporate Round | 100M |
| 10/2022 | Neumora Therapeutics | Series B | 0 |
| 10/2021 | Neumora Therapeutics | Corporate Round | 0 |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 12/2020 | SomaLogic | Series A | 0 |
| 8/2020 | Science 37 | Venture Round | 0 |
| 12/2019 | Keck Graduate Institute | Grant | 0 |
| 10/2019 | BeiGene | Post-IPO Equity | 0 |
| 10/2018 | Oxford Nanopore Technologies | Venture Round | 0 |
| 10/2017 | immatics biotechnologies | Series E | 0 |
| 6/2017 | Darmiyan | Non Equity Assistance | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 9/2010 | Private Placement | - | 2/2020 | Post-IPO Debt | $4B | 12/2022 | Post-IPO Debt | $28.5B | 4/1980 | Debt | $19M | 6/1983 | IPO | $40M | 7/2011 | Private Placement | - | 9/2010 | Private Placement | - |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 12/2022 | Horizon Pharma | |
| 8/2022 | ChemoCentryx | |
| 7/2021 | TeneoBio | |
| 3/2021 | Rodeo Therapeutics | |
| 3/2021 | Five Prime Therapeutics | |
| 11/2019 | Otezla | |
| 5/2019 | Nuevolution | |
| 12/2015 | Catherex | |
| 9/2015 | Dezima Pharma | |
| 8/2013 | Onyx Pharmaceuticals |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
